Balance Sheet
AssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Retained Earnings (2019 - 2025)

Benitec Biopharma's Retained Earnings history spans 7 years, with the latest figure at -$716000.0 for Q1 2025.

  • For Q1 2025, Retained Earnings rose 99.61% year-over-year to -$716000.0; the TTM value through Mar 2025 reached -$716000.0, up 99.61%, while the annual FY2024 figure was -$892000.0, 7.47% down from the prior year.
  • Retained Earnings for Q1 2025 was -$716000.0 at Benitec Biopharma, up from -$202.7 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$716000.0 in Q1 2025 and bottomed at -$202.7 million in Q4 2024.
  • The 5-year median for Retained Earnings is -$1.5 million (2022), against an average of -$71.0 million.
  • The largest annual shift saw Retained Earnings crashed 20084.86% in 2023 before it skyrocketed 99.61% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$1.3 million in 2021, then increased by 29.46% to -$898000.0 in 2022, then plummeted by 20084.86% to -$181.3 million in 2023, then dropped by 11.81% to -$202.7 million in 2024, then soared by 99.65% to -$716000.0 in 2025.
  • Per Business Quant, the three most recent readings for BNTC's Retained Earnings are -$716000.0 (Q1 2025), -$202.7 million (Q4 2024), and -$993000.0 (Q3 2024).